Company Overview - Sensus Healthcare, Inc. (SRTS) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance [4] Performance Metrics - Over the past week, SRTS shares increased by 1.54%, slightly outperforming the Zacks Medical - Instruments industry, which rose by 1.53% [6] - In the last month, SRTS shares rose by 3.36%, significantly better than the industry's performance of 0.98% [6] - For a longer-term perspective, SRTS shares have appreciated by 6.6% over the past quarter and an impressive 107.72% over the last year, compared to the S&P 500's gains of 6.49% and 25.94%, respectively [7] Trading Volume - The average 20-day trading volume for SRTS is 257,456 shares, which serves as a useful indicator of market interest and price movement [8] Earnings Outlook - Recent earnings estimate revisions for SRTS show one upward revision for the full year, increasing the consensus estimate from $0.29 to $0.36 over the past 60 days [10] - For the next fiscal year, there has been one upward revision with no downward revisions during the same period, indicating positive earnings momentum [10]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Sensus Healthcare, Inc. (SRTS) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Sensus Healthcare, Inc. is one of 1017 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank in ...

Shares of Sensus Healthcare, Inc. (SRTS) have gained 1.1% over the past four weeks to close the last trading session at $6.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.67 indicates a potential upside of 65.7%. The average comprises three short-term price targets ranging from a low of $10 to a high of $12, with a standard deviation of $1.15. While the lowest estimate i ...

Slavica/E+ via Getty Images Investment Thesis Sensus Healthcare (NASDAQ:NASDAQ:SRTS) is a company that offers equipment to treat skin problems, including non-melanoma cancer. These products have shown strong demand, but are usually affected during economically unstable periods such as 2020 and 2023, causing years as bad as the previous one. During 2024 the company has been recovering and management has begun exciting initiatives to create recurring revenue streams to provide more stability and also recently ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Sensus Healthcare, Inc. (SRTS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Sensus Healthcare, Inc. is one of 1019 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank conside ...

From a technical perspective, Sensus Healtheare, Inc. (SRTS) is looking like an interesting pick, as it just reached a key level of support. SRTS recently overtook the 20-day moving average, and this suggests a short-term bullish trend. The 20-day simple moving average is a well-liked trading tool because it provides a look back at a stock's price over a 20-day period. Additionally, short- term traders find this SMA very beneficial, as it smooths out short-term price trends and shows more trend reversal sig ...

Financial Performance - Revenues for the three months ended June 30, 2024, were $9.2 million, an increase of 104.4% compared to $4.5 million for the same period in 2023[79] - Gross profit for the three months ended June 30, 2024, was $5.4 million, representing a 107.7% increase from $2.6 million in the same period in 2023[81] - Net income for the three months ended June 30, 2024, was $1.6 million, compared to a net loss of $0.4 million for the same period in 2023[78] - Revenues for the six months ended June 30, 2024, were $20.0 million, an increase of 151.9% compared to $8.0 million for the same period in 2023[83] - Gross profit for the six months ended June 30, 2024, was $12.1 million, an increase of 188.1% from $4.2 million in the same period in 2023[84] Cash Flow and Receivables - Cash and cash equivalents decreased by $4.1 million from December 31, 2023, to June 30, 2024[89] - Accounts receivable increased by $7.7 million from December 31, 2023, primarily due to increased sales and extended payment terms[89] Expenses - Selling and marketing expenses decreased by 37.5% to $1.0 million for the three months ended June 30, 2024, compared to $1.6 million for the same period in 2023[82] - Research and development expenses increased by 12.5% to $0.9 million for the three months ended June 30, 2024, due to a project for a drug delivery system[83] Economic Factors - The company continues to monitor inflationary pressures and is taking actions to minimize its effects on product costs and sales[94]

Core Viewpoint - Sensus Healthcare, Inc. (SRTS) shows potential for significant upside, with a mean price target of $10 indicating a 64.7% increase from the current price of $6.07 [1] Price Target Analysis - The mean estimate consists of three short-term price targets with a standard deviation of $0, indicating strong agreement among analysts [2] - The lowest estimate of $10 suggests a 64.7% increase from the current price, while the most optimistic analyst also expects the stock to reach $10 [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [5][6] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding SRTS's ability to report better earnings than previously predicted supports the potential for stock upside [4] - A positive trend in earnings estimate revisions has a strong correlation with near-term stock price movements [9] - Over the last 30 days, two earnings estimates for SRTS have increased, leading to a 20% rise in the Zacks Consensus Estimate [10] Zacks Rank and Investment Potential - SRTS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] - While the consensus price target may not be a reliable indicator of potential gains, the implied direction of price movement appears to be a good guide [11]

Financial Data and Key Metrics Changes - Revenues for Q2 2024 more than doubled to $9.2 million, up 104% from $4.5 million in Q2 2023, driven by a higher number of SRT systems sold [9][12] - Net income for Q2 2024 was $1.6 million or $0.10 per diluted share, compared to a net loss of $0.4 million or $0.02 per share in Q2 2023 [11] - Adjusted EBITDA for Q2 2024 was $2.1 million compared to negative $1 million in Q2 2023 [11] Business Line Data and Key Metrics Changes - The company shipped 23 systems during Q2 2024, compared to 13 systems in the same quarter last year [4][9] - The Fair Deal Agreement program has 15 signed contracts, with expectations to reach up to 50 by year-end [5][17] Market Data and Key Metrics Changes - The company has expanded its international sales, with the first-ever image-guided SRT-100 Vision system sold in Asia [8] - The largest market outside the U.S. remains China, where two additional SRT-100 systems were shipped [8] Company Strategy and Development Direction - The company is focusing on a recurring revenue model through the Fair Deal Agreement, which allows customers to allocate capital to other areas of their business [5][17] - The company aims to open two to three new international territories per year, having successfully opened sales to Ireland, Guatemala, and Turkey [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential of SRT treatments for non-melanoma skin cancer and keloids, citing a 27% annual growth rate in Medicare claims for SRT [18] - The company anticipates significant recurring revenues beginning in 2025, with a strong volume projected for the second half of that year [5][18] Other Important Information - Cash and cash equivalents were $19 million as of June 30, 2024, down from $23.1 million at the end of 2023 [14][15] - The company is focused on maintaining a strong balance sheet to capitalize on growth opportunities [15] Q&A Session Summary Question: Can you provide details on the Fair Deal Agreement placements? - Management confirmed that all placements will be installed this year, primarily in Q4, allowing for revenue generation starting in early 2025 [20] Question: What is the total number of agreements signed to date? - Management confirmed that there are currently 15 agreements signed since the introduction of the program in March [22] Question: Are you supply constrained this year due to orders? - Management indicated that they have sufficient supply to meet customer needs and have placed orders for additional units [23] Question: How should we model the Fair Deal Agreements going into next year? - Management suggested that the Fair Deal Agreement provides reasonable terms for customers, making it easier for them to implement [24] Question: Can you provide a breakdown of domestic and international sales? - Management confirmed that out of 23 total sales, 20 were domestic and 3 were international [38]

Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 233.33%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced earnings of $0.14, delivering a surprise of 450%. Over the last four quarters, the compa ...